Induction of potent antitumor immunity by in situ targeting of intratumoral DCs
J. Clin. Invest. Katsuyoshi Furumoto, et al. 113:774 doi:10.1172/JCI19762 [Go to this article.]

Figure 4
CCL20 + CpG but not Flt3L + CpG induces a therapeutic antitumor response against B16 melanoma. (A and B) Graphs show tumor growth and survival of mice inoculated with 5 × 10⁴ CCL20-transduced B16 tumor cells (CCL20) or mock-transduced tumor cells alone or in addition to two or five intratumoral injections of CpG or ODN-CTR. Arrows show the days of CpG injections. (C and D) Mice were inoculated with B16-CCL20–transduced tumor cells followed by two or five intratumoral injections of CpG or with B16-mock–transduced tumor cells followed by two or five intratumoral CpG injections alone or in addition to eight daily injections of Flt3L beginning on the day of tumor inoculation (mock + CpG + Flt3L). Results shown are representative of six different experiments in A and B and two different experiments in C and D. (A) P < 0.05 between CCL20 + CpG and control groups. (B) Survival rate was higher in mice treated with CCL20 + 5 CpG compared with mock + 5 CpG (P < 0.0001) or to CCL20 + 5 ODN-CTR (P = 0.0006). (C) P < 0.05 between CCL20 + CpG and the other groups. (D) Survival rate was significantly higher in mice treated with CCL20 + CpG compared with mock + CpG + Flt3L (P = 0.0012). *P < 0.05.